


## **CLAIMS**

### 1. A compound of the formula




wherein R<sup>1</sup> is (C<sub>1</sub>-C<sub>6</sub>)alkyl, optionally substituted by (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl, (C<sub>6</sub>-C<sub>10</sub>)aryl,

5 (C<sub>1</sub>-C<sub>10</sub>)heterocyclyl, or (C<sub>1</sub>-C<sub>10</sub>)heteroaryl; wherein each of said (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl, (C<sub>6</sub>-C<sub>10</sub>)aryl, (C<sub>1</sub>-C<sub>10</sub>)heterocyclyl, or (C<sub>1</sub>-C<sub>10</sub>)heteroaryl are optionally substituted by one to three suitable moieties independently selected from the group consisting of hydroxy, halogen, CN-, (C<sub>1</sub>-C<sub>6</sub>)alkyl, HO(C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkyl-NH(C=O)-, NH<sub>2</sub>(C=O)-, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, or (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl, wherein said (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl is optionally substituted  
10 by one or more moieties selected from halogen, or (C<sub>1</sub>-C<sub>6</sub>)alkyl-;

R<sup>2</sup> is hydrogen, halogen, -CN, and (C<sub>1</sub>-C<sub>6</sub>)alkyl, wherein said (C<sub>1</sub>-C<sub>6</sub>)alkyl is optionally substituted by one to three suitable moieties, independently selected from the group consisting of halo, hydroxy, amino, -CN, (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, -CF<sub>3</sub>, CF<sub>3</sub>O-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-NH-, [(C<sub>1</sub>-C<sub>6</sub>)alkyl]<sub>2</sub>N-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-S-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-(S=O)-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-(SO<sub>2</sub>)-,


15 (C<sub>1</sub>-C<sub>6</sub>)alkyl-O-(C=O)-, formyl, (C<sub>1</sub>-C<sub>6</sub>)alkyl-(C=O)-, and (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl; and

$R^3$  is a suitably substituted nitrogen linked ( $C_1$ - $C_{10}$ )heterocyclyl of the formula:



or the pharmaceutically acceptable salts or solvates or prodrugs thereof.


## 2. A compound of the formula



wherein R<sup>1</sup> is (C<sub>1</sub>-C<sub>6</sub>)alkyl, optionally substituted by (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl, (C<sub>6</sub>-C<sub>10</sub>)aryl, (C<sub>1</sub>-C<sub>10</sub>)heterocyclyl, or (C<sub>1</sub>-C<sub>10</sub>)heteroaryl, wherein each of said (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl, (C<sub>6</sub>-C<sub>10</sub>)aryl, (C<sub>1</sub>-C<sub>10</sub>)heterocyclyl, or (C<sub>1</sub>-C<sub>10</sub>)heteroaryl are optionally substituted by one to three suitable moieties independently selected from the group consisting of hydroxy, halogen, CN-, (C<sub>1</sub>-C<sub>6</sub>)alkyl, HO(C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkyl-NH(C=O)-, NH<sub>2</sub>(C=O)-, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, or (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl, wherein said (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl is optionally substituted by one or more moieties selected from halogen, or (C<sub>1</sub>-C<sub>6</sub>)alkyl-;

R<sup>2</sup> is hydrogen, halogen, -CN, and (C<sub>1</sub>-C<sub>6</sub>)alkyl, wherein said (C<sub>1</sub>-C<sub>6</sub>)alkyl is optionally substituted by one to three suitable moieties, independently selected from the group consisting of halo, hydroxy, amino, -CN, (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, -CF<sub>3</sub>, CF<sub>3</sub>O-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-NH-, [(C<sub>1</sub>-C<sub>6</sub>)alkyl]<sub>2</sub>-N-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-S-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-(S=O)-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-(SO<sub>2</sub>)-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-O-(C=O)-, formyl, (C<sub>1</sub>-C<sub>6</sub>)alkyl-(C=O)-, and (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl;

R<sup>3</sup> is a nitrogen linked (C<sub>1</sub>-C<sub>10</sub>)heterocyclyl of the formula:



15

IV

V

wherein R<sup>4</sup> and R<sup>5</sup> are independently selected from the group of suitable substituents, such as hydrogen, halo, hydroxy, -CN, HO-(C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkyl, wherein said (C<sub>1</sub>-C<sub>6</sub>)alkyl is optionally substituted with one to three fluoro, (C<sub>1</sub>-C<sub>6</sub>)alkoxy optionally substituted with one to three fluoro, HO<sub>2</sub>C-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-O-(C=O)-, R<sup>6</sup>R<sup>8</sup>N(O<sub>2</sub>S)-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-(O<sub>2</sub>S)-NH-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-O<sub>2</sub>S-[(C<sub>1</sub>-C<sub>6</sub>)alkyl-N]-, R<sup>6</sup>R<sup>8</sup>N(C=O)-, R<sup>6</sup>R<sup>8</sup>N(CH<sub>2</sub>)<sub>m</sub>-, (C<sub>6</sub>-C<sub>10</sub>)aryl, (C<sub>3</sub>-C<sub>8</sub>)cycloalkyl, (C<sub>1</sub>-C<sub>10</sub>)heteroaryl, (C<sub>1</sub>-C<sub>10</sub>)heterocyclyl, (C<sub>6</sub>-C<sub>10</sub>)aryl-O-, (C<sub>3</sub>-C<sub>8</sub>)cycloalkyl-O-, (C<sub>1</sub>-C<sub>10</sub>)heteroaryl-O- and (C<sub>1</sub>-C<sub>10</sub>)heterocyclyl-O-; and

R<sup>7</sup> is independently selected from the group of suitable substituents such as hydrogen and (C<sub>1</sub>-C<sub>6</sub>)alkyl optionally substituted with one to three halogens, hydroxy, -CN, (C<sub>1</sub>-C<sub>6</sub>)alkoxy-, (C<sub>2</sub>-C<sub>6</sub>)alkenoxy, (C<sub>1</sub>-C<sub>6</sub>)alkyl-SO<sub>2</sub>-, NH<sub>2</sub>-, ((C<sub>1</sub>-C<sub>6</sub>)alkyl)<sub>n</sub>-N-, ((C<sub>2</sub>-C<sub>6</sub>)alkenyl)<sub>n</sub>-N-, ((C<sub>2</sub>-C<sub>6</sub>)alkynyl)<sub>n</sub>-N-, NH<sub>2</sub>(C=O)-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-(C=O)N-, ((C<sub>1</sub>-C<sub>6</sub>)alkyl)<sub>n</sub>-N-(C=O)-, (C<sub>2</sub>-C<sub>6</sub>)alkenyl-(C=O)N-, ((C<sub>2</sub>-C<sub>6</sub>)alkenyl)<sub>n</sub>-N-(C=O)-, (C<sub>2</sub>-C<sub>6</sub>)alkynyl-(C=O)N-, ((C<sub>2</sub>-C<sub>6</sub>)alkynyl)<sub>n</sub>-N-(C=O)-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-(C=O)-, (C<sub>2</sub>-C<sub>6</sub>)alkenyl-(C=O)-, (C<sub>2</sub>-C<sub>6</sub>)alkynyl-(C=O)-, (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl-(C=O)-, ((C<sub>1</sub>-C<sub>10</sub>)heterocyclyl-(C=O)-, (C<sub>6</sub>-C<sub>10</sub>)aryl-(C=O), (C<sub>1</sub>-C<sub>10</sub>)heteroaryl-(C=O), (C<sub>1</sub>-C<sub>6</sub>)alkyl-(C=O)O-, (C<sub>2</sub>-C<sub>6</sub>)alkenyl-(C=O)O-, (C<sub>2</sub>-C<sub>6</sub>)alkynyl-(C=O)O-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-O(C=O)-,

(C<sub>2</sub>-C<sub>6</sub>)alkenyl-O-(C=O)-, (C<sub>2</sub>-C<sub>6</sub>)alkynyl-O-(C=O)-, (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl, (C<sub>6</sub>-C<sub>10</sub>)aryl, (C<sub>1</sub>-C<sub>10</sub>)heterocyclyl, and (C<sub>1</sub>-C<sub>10</sub>)heteroaryl;

wherein R<sup>4</sup>, R<sup>5</sup> and R<sup>7</sup> may each be optionally substituted on any aliphatic or aromatic carbon atom by one to three suitable moieties, independently selected from the group consisting of halo, hydroxy, amino, -CN, (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, -CF<sub>3</sub>, CF<sub>3</sub>O-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-NH-, [(C<sub>1</sub>-C<sub>6</sub>)alkyl]<sub>2</sub>-N-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-S-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-(S=O)-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-(SO<sub>2</sub>)-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-O-(C=O)-, formyl, (C<sub>1</sub>-C<sub>6</sub>)alkyl-(C=O)-, and (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl;

5 R<sup>6</sup> and R<sup>8</sup> are each independently selected from the group consisting of hydrogen, (C<sub>1</sub>-C<sub>6</sub>)alkyl, HO-(C<sub>2</sub>-C<sub>6</sub>)alkyl and (C<sub>3</sub>-C<sub>8</sub>)cycloalkyl, or R<sup>6</sup> and R<sup>8</sup> may optionally be taken 10 together with the nitrogen atom to which they are attached to form a 3 to 8 membered heterocycle;


n is an integer from zero to two; and

m is an integer from one to two;

or the pharmaceutically acceptable salts or solvates or prodrugs thereof.

15 3. A compound of any of the preceding claims wherein R<sup>2</sup> is chloro, methyl or ethyl.




4. A compound of any of the preceding claims wherein R<sup>3</sup> is a nitrogen linked (C<sub>1</sub>-C<sub>10</sub>)heterocyclyl of formula (IV):




20

R<sup>4</sup> is hydrogen or methyl,


and R<sup>7</sup> is selected from the group consisting of:




5. A compound of any of the preceding claims wherein  $R^3$  is a nitrogen linked ( $C_1$ - $C_{10}$ )heterocycl of formula (IV),  $R^4$  is hydrogen or methyl, and  $R^7$  is





6. A compound of any of the preceding claims wherein  $R^3$  is a nitrogen linked  
5 ( $C_1$ - $C_{10}$ )heterocyclyl of formula (IV),  $R^4$  is hydrogen or methyl, and  $R^7$  is selected from the  
group consisting of:




7. A compound of any of the preceding claims wherein  $R^3$  is a nitrogen linked ( $C_1$ - $C_{10}$ )heterocyclyl of formula (IV),  $R^4$  is hydrogen or methyl, and  $R^7$  is



8. A compound of any of the preceding claims wherein  $R^3$  is a nitrogen linked ( $C_1-C_{10}$ )heterocyclol of formula (IV),  $R^4$  is hydrogen or methyl, and  $R^7$  is selected from:



9. A compound of any of the preceding claims wherein  $R^3$  is a nitrogen linked  
15 ( $C_1$ - $C_{10}$ )heterocycl of formula (IV),  $R^4$  is hydrogen or methyl, and  $R^7$  is selected from:



10. A compound selected from the group consisting of:

2-Chloro-N-(1-hydroxy-cycloheptylmethyl)-5-[4-(2-methoxy-ethyl)-5-oxo-4,5-dihydro-[1,2,4]triazol-1-yl]-benzamide;

5 2-Chloro-N-(1-hydroxy-cycloheptylmethyl)-5-(5-oxo-4,5-dihydro-[1,2,4]triazol-1-yl)-benzamide;

2-Chloro-N-(1-hydroxy-cycloheptylmethyl)-5-(3-methyl-5-oxo-4,5-dihydro-[1,2,4]triazol-1-yl)-benzamide;

10 2-Chloro-N-(1-hydroxy-cycloheptylmethyl)-5-[4-(2-hydroxy-ethyl)-5-oxo-4,5-dihydro-[1,2,4]triazol-1-yl]-benzamide;

2-Chloro-5-(4-cyanomethyl-5-oxo-4,5-dihydro-[1,2,4]triazol-1-yl)-N-(1-hydroxy-cycloheptylmethyl)-benzamide;

15 2-Chloro-N-(1-hydroxy-cycloheptylmethyl)-5-[4-(2-methoxy-ethyl)-3-methyl-5-oxo-4,5-dihydro-[1,2,4]triazol-1-yl]-benzamide;

2-Chloro-5-(4-cyanomethyl-3-methyl-5-oxo-4,5-dihydro-[1,2,4]triazol-1-yl)-N-(1-hydroxy-cycloheptylmethyl)-benzamide;

20 2-Chloro-N-(1-hydroxy-3,3-dimethyl-cyclohexylmethyl)-5-(3-methyl-5-oxo-4,5-dihydro-[1,2,4]triazol-1-yl)-benzamide;

5-(4-Carbamoylmethyl-3-methyl-5-oxo-4,5-dihydro-[1,2,4]triazol-1-yl)-2-chloro-N-(1-hydroxy-cycloheptylmethyl)-benzamide;

25 2-Chloro-N-(1-hydroxy-cycloheptylmethyl)-5-[4-(2-hydroxy-ethyl)-3-methyl-5-oxo-4,5-dihydro-[1,2,4]triazol-1-yl]-benzamide;

5-[4-(2-Amino-ethyl)-3-methyl-5-oxo-4,5-dihydro-[1,2,4]triazol-1-yl]-2-chloro-N-(1-hydroxy-cycloheptylmethyl)-benzamide;

2-Chloro-N-(1-hydroxy-cycloheptylmethyl)-5-[4-(2-hydroxy-3-methoxy-propyl)-3-methyl-5-oxo-4,5-dihydro-[1,2,4]triazol-1-yl]-benzamide;

2-Chloro-N-(1-hydroxy-cycloheptylmethyl)-5-[4-(2-hydroxy-3-methoxy-propyl)-3-methyl-5-oxo-4,5-dihydro-[1,2,4]triazol-1-yl]-benzamide;

5 2-Chloro-N-(1-hydroxy-cycloheptylmethyl)-5-[4-(2-hydroxy-2-methyl-propyl)-3-methyl-5-oxo-4,5-dihydro-[1,2,4]triazol-1-yl]-benzamide.

10 11. A pharmaceutical composition for treating a IL-1 mediated disease in a mammal in need thereof, comprising a therapeutically effective amount of a compound according to claim 1 or a salt or prodrug thereof, and a pharmaceutically acceptable carrier or diluent.

12. A method of treating a IL-1 mediated disease in a mammal in need thereof, comprising administering to said mammal a therapeutically effective amount of a compound according to claim 1 or a salt or prodrug thereof.